Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899767 | 0.87 | NR1H4 (0.46) | NR1H4PTGER1HTR1AADRA1DADRA1A | |
| SCHEMBL6902570 | 0.82 | LTB4R (0.52) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6806859 | 0.78 | LTB4R (0.47) | LTB4RLTB4R2 | |
| SCHEMBL8581492 | 0.78 | HTR1A (0.51) | NR1H4HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL8585279 | 0.77 | NR1H4 (0.47) | NR1H4HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6807773 | 0.77 | NR1H4 (0.47) | NR1H4HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL7615372 | 0.76 | SLC6A9 (0.39) | SLC6A9PTGER1ADRA1DADRA1AADRA1B | |
| SCHEMBL8582404 | 0.76 | NR1H4 (0.46) | NR1H4HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6807260 | 0.74 | NR1H4 (0.60) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6899274 | 0.73 | NR1H4 (0.48) | NR1H4HTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | SAWYER JASON SCOTT (US) | 2004-10-07 | — | — | US | disclosed |
| US-6797723-B1 | Heterocycle substituted diphenyl leukotriene antagonists | ELI LILLY AND COMPANY | 2004-09-28 | — | — | US | disclosed |
| CN-1387518-A | Heterocyclic substituted diphenyl leukotriene antagonists | LILLY CO ELI (US) | 2002-12-25 | — | — | CN | disclosed |
| EP-1263743-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1231939-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1231938-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034197-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034198-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034137-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034580-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034135-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | LTB4R, LTB4R2, LTA4H | SLC6A9 4588/4885NR1H4 233/4885PTGER1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.